New drugs are not enough-drug repositioning in oncology: An update

被引：64
|
作者：
Armando, Romina Gabriela [1 ]
Gomez, Diego Luis Mengual [1 ]
Gomez, Daniel Eduardo [1 ]
机构：
[1] Natl Univ Quilmes, Sci & Technol Dept, Lab Mol Oncol, Roque Saenz Pena 352,B1876, Bernal, Argentina
来源：
INTERNATIONAL JOURNAL OF ONCOLOGY | 2020年 / 56卷 / 03期
关键词：
drug; repositioning; repurposing; oncology; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HIV PROTEASE INHIBITORS; CANCER STEM-CELLS; PHOSPHODIESTERASE TYPE 5; HUMAN PROSTATE-CANCER; PHASE-II TRIAL; OVEREXPRESSING TISSUE INHIBITOR; MYELOID-LEUKEMIA MECHANISMS; CALCIUM-CHANNEL ANTAGONISTS; ENDOTHELIAL GROWTH-FACTOR;
D O I：
10.3892/ijo.2020.4966
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Drug repositioning refers to the concept of discovering novel clinical benefits of drugs that are already known for use treating other diseases. The advantages of this are that several important drug characteristics are already established (including efficacy, pharmacokinetics, pharmacodynamics and toxicity), making the process of research for a putative drug quicker and less costly. Drug repositioning in oncology has received extensive focus. The present review summarizes the most prominent examples of drug repositioning for the treatment of cancer, taking into consideration their primary use, proposed anticancer mechanisms and current development status.
引用
收藏
页码：651 / 684
页数：34
相关论文
共 50 条
  • [31] Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach
    Sita Sirisha Madugula
    Selvaraman Nagamani
    Esther Jamir
    Lipsa Priyadarsinee
    G. Narahari Sastry
    Molecular Diversity, 2022, 26 : 1675 - 1695
  • [32] An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
    Bhattarai, Deepak
    Singh, Sarbijt
    Jang, Yerin
    Han, Seung Hyeon
    Lee, Kyeong
    Choi, Yongseok
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (19) : 2156 - 2168
  • [33] Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach
    Madugula, Sita Sirisha
    Nagamani, Selvaraman
    Jamir, Esther
    Priyadarsinee, Lipsa
    Sastry, G. Narahari
    MOLECULAR DIVERSITY, 2022, 26 (03) : 1675 - 1695
  • [34] DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information
    I Amelio
    M Gostev
    R A Knight
    A E Willis
    G Melino
    A V Antonov
    Cell Death & Disease, 2014, 5 : e1051 - e1051
  • [35] Drug repositioning of anti-inflammatory drugs in major psychiatric disorders
    Fond, G.
    Hamdani, N.
    Leboyer, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S185 - S185
  • [36] Drug repositioning through integration of prior knowledge and projections of drugs and diseases
    Xuan, Ping
    Cao, Yangkun
    Zhang, Tiangang
    Wang, Xiao
    Pan, Shuxiang
    Shen, Tonghui
    BIOINFORMATICS, 2019, 35 (20) : 4108 - 4119
  • [37] Exploration of Therapeutic Drugs for Gastric Cancer Using Drug Repositioning Strategy
    Qi X.
    Xun D.
    Feng S.
    Gao N.
    Hou S.
    Lu Y.
    Huang L.
    Chen J.
    Dianzi Keji Daxue Xuebao/Journal of the University of Electronic Science and Technology of China, 2023, 52 (05): : 659 - 666
  • [38] Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets
    Mudduluru, Giridhar
    Walther, Wolfgang
    Kobelt, Dennis
    Dahlmann, Mathias
    Treese, Christoph
    Assaraf, Yehuda G.
    Stein, Ulrike
    DRUG RESISTANCE UPDATES, 2016, 26 : 10 - 27
  • [39] An update on hybrid drugs in cardiovascular drug research
    Calderone, Vincenzo
    EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (12) : 1397 - 1408
  • [40] New targets and new drugs in thoracic oncology
    Rouviere, D.
    Bousquet, E.
    Pons, E.
    Milia, J. -D.
    Guibert, N.
    Mazieres, J.
    REVUE DES MALADIES RESPIRATOIRES, 2015, 32 (08) : 867 - 876
12345